---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-000406"
form_type: "8-K"
ticker: "ANEB"
cik: "0001815974"
company_name: "Anebulo Pharmaceuticals, Inc."
filed_at: "2022-01-05T23:59:59+00:00"
generated_at: "2026-06-27T20:41:58.391459+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Anebulo Pharmaceuticals names Simon Allen CEO effective Feb 1, 2022; Dr. Schneeberger resigns

## Summary
- Simon Allen appointed CEO and director, effective Feb 1, 2022; succeeds Daniel Schneeberger.
- Dr. Schneeberger's resignation not due to any disagreement with company operations or policies.
- Allen receives $450k base salary; stock options for 625k shares at $6.21 vesting quarterly over 4 years.
- Allen eligible for $1.5M cash bonus if company sold for ≥$500M with Board approval.
- Severance of 9 months base salary plus COBRA reimbursement for 12 months if terminated without cause.

## SEC filing metadata
- accession: 0001493152-22-000406
- form_type: 8-K
- ticker: ANEB
- cik: 0001815974
- company_name: Anebulo Pharmaceuticals, Inc.
- filed_at: 2022-01-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815974/000149315222000406/0001493152-22-000406-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815974/000149315222000406/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-000406
- JSON: https://secwatch.observer/filing/0001493152-22-000406.json
- Plain text: https://secwatch.observer/filing/0001493152-22-000406.txt

## Key facts
- Executive change
  Simon Allen was elected as Member of the Board of Directors at Anebulo Pharmaceuticals, Inc..
  - Action: elected
  - Role: Member of the Board of Directors
  source text: On January 3, 2022, Simon Allen was appointed to be our Chief Executive Officer and elected a member of our Board of Directors, both to be effective on February 1, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815974/000149315222000406/0001493152-22-000406-index.htm
- Executive change
  Daniel Schneeberger resigned as Chief Executive Officer at Anebulo Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Chief Executive Officer
  source text: Daniel Schneeberger, M.D. resigned such positions in order to bring in Mr. Allen.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815974/000149315222000406/0001493152-22-000406-index.htm
- Executive change
  Daniel Schneeberger resigned as Director at Anebulo Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Director
  source text: Daniel Schneeberger, M.D. resigned such positions in order to bring in Mr. Allen.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815974/000149315222000406/0001493152-22-000406-index.htm
- Executive change
  Simon Allen was appointed as Chief Executive Officer at Anebulo Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: On January 3, 2022, Simon Allen was appointed to be our Chief Executive Officer and elected a member of our Board of Directors, both to be effective on February 1, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815974/000149315222000406/0001493152-22-000406-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.